A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study includes Single agent/combination dose exploration study and the phase II study.
The primary purpose of this study is to determine the maximum tolerated dose(MTD)/recommended
phase II dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive,
human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.